Acceptance of an Mpox Vaccine in the Democratic Republic of the Congo

Skylar Petrichko[1]*, Jason Kindrachuk[2]*, Dalau Nkamba[3], Megan Halbrook[1], Sydney Merritt[1], Handdy Kalengi[3], Leonard Kamba[3], Michael Beya[3], Nicole A. Hoff[1], Christophe Luhata[4], Didine K. Kaba[3#], Anne W. Rimoin[1#]

* Denotes co-first authors. These authors contributed equally to this article.

# Denotes co-last authors

Author Affiliation:

1. Department of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, CA, USA
2. Department of Medical Microbiology & Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada
3. Kinshasa School of Public Health, University of Kinshasa, Democratic Republic of the Congo
4. Expanded Programme for Immunization, Ministry of Health, Democratic Republic of the Congo

Corresponding Author:

Anne W. Rimoin, PhD, MPH
Professor, Department of Epidemiology, Gordon-Levin Endowed Chair in Infectious Diseases and Public Health
Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles
650 Charles E. Young Dr, CHS 41-275, Los Angeles, CA, 90095
+1 (310) 825-2096, arimoin@ucla.edu

KEYWORDS mpox; vaccination; Democratic Republic of the Congo; MPXV

WORD COUNTS Abstract - 48; Text - 1289

ABSTRACT

We report general acceptance of an mpox vaccine (61.0%) in the Democratic Republic of the Congo (n = 5226) with higher acceptance among healthcare workers and respondents in historic mpox-endemic regions. These data highlight the need for increased community engagement and sensitization before widespread deployment of mpox vaccines.

INTRODUCTION

Mpox is a zoonotic infectious disease endemic to the Democratic Republic of the Congo (DRC) (1-3). In 2022, rapid spread of MPXV Clade IIb worldwide resulted in over 91,000 confirmed infections and the declaration of a public health emergency of international concern (PHEIC) (4). In the DRC incident cases have quadrupled between 2021 and 2023: over 28,000 suspected cases were reported from January 2023 to July 2024, and new introductions recorded in neighboring Burundi, Rwanda, Kenya, and Uganda (5). In August 2024 a travel-associated Clade Ib case was reported for the first time in Sweden (6). In response to the recent expanding burden of mpox, Africa CDC and the WHO declared a Public Health Emergency of Continental Security and second PHEIC, respectively.

Despite the deployment of a modified vaccinia Ankara-Bavarian Nordic vaccine to many high and middle-income countries, there currently is no mpox vaccine access for the general population in Africa. One vaccination model suggests that vaccination of 80% of children under 15 years old in DRC would result in robust reductions on morbidity, mortality, and mpox circulation (7).

METHODS

The data for this cross-sectional analysis was drawn from a larger longitudinal phone survey which began in 2022 and included participants, targeting primarily HCWs, from all 26 provinces in the DRC. Participants were selected from historical phone survey records of over 10,000 persons. From these records, 5,226 adult participants were contacted between December 2023 to February 2024 by study staff to complete to this vaccine survey. Surveys were administered via phone by trained interviewers in Swahili, French, Lingala, Kikongo, and/or Tshiluba. Survey questions included behavioral and social drivers of vaccination and attitudes towards the introduction of new vaccines, including mpox. Mpox vaccine acceptance was measured by asking participants about their interest in the inclusion of a an mpox vaccine in the national vaccination schedule and participants were given several response choices—yes, for either adults, children or both; no; and I do not know this disease (Supplementary Material 1). All ‘yes’ responses were collapsed for analysis. Attitudes, vaccine acceptance by province, and sociodemographic characteristics were assessed via Likert scale questions and presented as a 5- or 3-level variable and chi-square test (α=0.05).

Ethics approval was provided by the Kinshasa School of Public Health (ESP/CE/188/2023) and the University of California, Los Angeles, as a public health response activity designation.

RESULTS

Respondents were predominantly male (79.2%), with the highest percentage from Kwilu province (12.6%). There was roughly equivalent representation of those from urban or rural settings. Most respondents reported some college/university education (41.2%) and identified as healthcare workers (55.5%) **(Table 1)**.

Participants generally disagreed with the statement that new vaccines carry more risks than older vaccines. However, in four provinces—Sud Kivu, Nord Ubangi, Nord Kivu, and Lualaba—more than 50% of respondents agreed with or felt that greater risks exist. Respondents generally agreed with the statement that information received about vaccines from the vaccination program was reliable and trustworthy. In Sankuru province, 29.5% of respondents felt neutral about the reliability of vaccine program information; Haut Katanga and Lomami had the highest prevalence of vaccine information distrust, with 7.6% and 6.8% disagreeing with the statement. **(Figure 1)**.

Nationally, there was general acceptance of an mpox vaccination by all respondents (61.0%, 95% CI:59.6-62.4); 21.7% had no interest, and 17.3% reported no knowledge of mpox. At the provincial level, more than 80% of respondents from Kwango, Tshuapa, Nord Ubangi, Tanganyika, and Maniema were accepting of a vaccine, while respondents from Sankuru had the lowest acceptance (19.9%, 95% CI:14.3-26.6). Sankuru also had the highest percentage of participants that reported no mpox knowledge (57.4%, 95% CI:49.7-64.8). In general, rates of mpox vaccine acceptance and mpox disease knowledge were not influenced by the history of mpox cases within the province **(Figure 2)**.

Mpox vaccine acceptance varied significantly by province ($p < 0.0001$). When stratified by educational attainment, those with a high school diploma had significantly lower acceptance of the mpox vaccine (49.8% 95%CI: 47.3-52.3) compared with others. Of all occupations reported, healthcare workers had the highest acceptance rates (69.4%, 95% CI: 67.6-71.1). Respondents from rural locations indicated greater acceptance of mpox vaccine deployment than their urban counterparts (64.4% vs 57.7%, $p<0.0001$). Among respondents who reported receiving a COVID-19 vaccine (n=4396), 63.2% indicated mpox vaccine acceptance. Additionally, persons who reported experiencing no chronic conditions reported higher rates of mpox vaccine acceptance (62.2% vs 51.0%) **(Figure 3)**.

CONCLUSION

Given the ongoing escalation of the concurrent DRC Clade Ia and Clade Ib outbreaks and recent identification of cases in adjacent countries in Central Africa, there is increasing need for the rapid introduction of an mpox vaccine. However, to date, there is a paucity of information regarding mpox vaccine acceptance and mpox knowledge across DRC. We observed greater interest in mpox vaccine deployment among respondents from rural locations compared with urban populations. This is perhaps explained by the historic burden of mpox in DRC as mpox

cases were primarily identified among children in rural regions. Currently, reported mpox cases are rising in urban centers, further challenging response and vaccine planning efforts.

Assessing mpox vaccine trust and acceptance across provinces that have and have not experienced mpox cases, and across demographic variables did not yield clear or neatly described trends. Instead, we observed several instances of outliers that may reflect the uniqueness and diversity of the DRC. For example, differing vaccine acceptance rates between those with and without chronic conditions may indicate underlying health anxieties among those with persistent health problems; further investigation is needed to better understand this relationship. Additionally, Sankuru province was consistently a vaccine hesitant outlier. Sankuru had the lowest proportion of respondents who trust information received from national vaccine programs and the lowest mpox vaccine acceptance, primarily because 57.4% of respondents stated no knowledge of mpox. In DRC, the majority of mpox endemic provinces consist of rainforest or forest-savannah mosaic geographies; the southeast provinces are primarily savanna and grassland and with no history of reported mpox cases. However, in June 2024 Lualaba reported their first mpox case. Interestingly, this province had the highest proportion of respondents believing that new vaccines have greater risks than older vaccines, though overall trust in national vaccine programs was high.

While these results report an overall trend of vaccine trust and acceptance nation-wide, they also indicate the need for a multifaceted approach to vaccine education and rollout. Strategies should be tailored to historically endemic regions and/or areas with lower vaccine acceptance, such as Sankuru or Kasai Central, and consider how personal experiences and cultural considerations intersect with mpox outbreaks. Of note, Haut Lomami province has been the setting of long-standing routine immunization revitalization efforts (8, 9), and 100% of respondents from this province reported that they feel information from the national vaccine program is reliable. This highly positive response is perhaps reflective of the many years of vaccine campaigns and education efforts in this region.

This survey was limited to those with access to phones; individuals with a lower socioeconomic status may have been inadvertently excluded from this study, including those in largely rural regions. This study included respondents from all provinces in DRC, with an emphasis on recruiting HCW. Past studies in the DRC have demonstrated 54% acceptance towards outbreak-related vaccines, with HCW continually expressing the highest acceptance among all respondents (10). As this study sought to enroll HCWs, and community and religious leaders, we observed an over-representation of men as they primarily hold these leadership roles in the DRC. As HCWs and religious leaders serve as health recommenders for their communities, there is a critical need to identify and address vaccine acceptance among these groups. These data provide insight regarding future deployments in adjacent regions as well as vaccine acceptance and deployment strategies within DRC, or regionally, for other emerging infectious diseases.

ACKNOWLEDGEMENTS

All cartographic figures were generated using qGIS (Maidenhead, 3.36.3). We thank Brooke Aksnes and Emma Wray Aberle-Grasse for their continued support of this ongoing research endeavor.

FUNDING

This work was supported by funding from the Centers for Disease Control and Prevention (CDC) through the Task Force for Global Health (TFGH) under Cooperative Agreement # 6 NU2RGH001916-02-06. The content of the information does not necessarily reflect the position or the policy of TFGH, and no official endorsement should be inferred.

REFERENCES

1. AI B. Human monkeypox, 1970-79. Bull World Health Organ. 1980;58:165182.
2. Foster SO, Brink EW, Hutchins DL, Pifer JM, Lourie B, Moser CR, et al. Human monkeypox. Bull World Health Organ. 1972;46(5):569-76.
3. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972;46(5):593-7.
4. (WHO) WHO. Mpox (monkeypox) Outbreak. Emergencies 2024 [cited 2024; Available from: https://www.who.int/europe/emergencies/situations/monkeypox
5. (SGI-MPOX) SdGdLEM. Epidemie de Mpox en Republique Democratique du Congo; Rapport de Situation No. 027. Kinshasa, DRC: Institut National de Sante Publique; 2024.
6. Mpox due to monkeypox virus clade I. Epidemiological Update: European Center for Disease Prevention and Control (ECDC); 2024.
7. Savinkina A, Kindrachuk J, Bogoch I, Rimoin AW, Hoff NA, Shaw SY, et al. Modeling Vaccination Approaches for Mpox Containment and Mitigation in the Democratic Republic of the Congo. Available at SSRN 4759169. 2024.
8. Lame P, Milabyo A, Tangney S, Mbaka GO, Luhata C, Gargasson JL, et al. A Successful National and Multipartner Approach to Increase Immunization Coverage: The Democratic Republic of Congo Mashako Plan 2018-2020. Glob Health Sci Pract. 2023 Apr 28;11(2).
9. Banza Mpiongo P, Kibanza J, Kambol Yav F, Nyombo D, Mwepu L, Basame D, et al. Strengthening immunization programs through innovative sub-national public-private partnerships in selected provinces in the Democratic Republic of the Congo. Vaccine. 2023 2023/12/12/;41(51):7598-607.
10. Peckeu-Abboud L, Mangoni P, Chammam K, Kwete P, Mutombo Lupola P, Vanlerberghe V, et al. Drivers of routine and outbreak vaccination uptake in the western Democratic Republic of Congo: an exploratory study in ten health zones. Vaccines. 2022;10(7):1066.

FIGURES AND TABLES

190 **Table 1. Demographic Characteristics of National Phone Survey Respondents (n = 5226)**

Sample characteristic[1]	Frequency n = 5226	
Demographics		
Age (median [IQR])	42	16.0
Gender		
Male	4138	(79.2%)
Female	1088	(20.8%)
Education Level		
Less than high school	359	(6.9%)
Graduated high school	1589	(30.4%)
Some college	2158	(41.3%)
Bachelor or advanced degree	1120	(21.4%)
Province		
Maindombe	134	(2.6%)
Kwango	183	(3.5%)
Kwilu	657	(12.6%)
Kongo Central	312	(6.0%)
Equateur	162	(3.1%)
Mongala	238	(4.6%)
Tshuapa	63	(1.2%)
Nord Ubangi	113	(2.2%)
Sud Ubangi	91	(1.7%)
Kasai Oriental	597	(11.4%)
Sankuru	176	(3.4%)
Lomami	192	(3.7%)
Kasai	118	(2.3%)
Kasai Central	87	(1.7%)
Haut Katanga	331	(6.3%)

Tanganyika	151	(2.9%)
Haut Lomami	50	(1.0%)
Lualaba	168	(3.2%)
Kinshasa	251	(4.8%)
Maniema	98	(1.9%)
North Kivu	140	(2.7%)
Bas Uele	246	(4.7%)
Haut Uele	137	(2.6%)
Ituri	239	(4.6%)
Tshopo	144	(2.8%)
Sud Kivu	148	(2.8%)
Geographic Area		
Urban	2659	(50.9%)
Rural	2567	(49.1%)
Occupation		
Health worker	2899	(55.5%)
Religious leader	89	(1.7%)
Community or essential services leader	768	(14.7%)
Public service sector or educator	670	(12.8%)
Other worker	513	(9.8%)
Not working	287	(5.5%)
Health Information		
Health conditions		
Chronic lung disease	32	(0.6%)
Diabetes	209	(4.0%)
Cardiovascular disease	254	(4.9%)
Chronic renal disease	12	(0.2%)
Chronic liver disease	9	(0.2%)
Immunocompromised	10	(0.2%)

No conditions	4700	(89.9%)

[1]Reported as n (%) unless otherwise noted.

[2]Abbreviations: IQR, Interquartile range

Figure 1. General Vaccine Attitudes and Perceptions by Province. (A) Reported responses to the statement "New vaccines carry more risks than older vaccines" (B) Reported responses to the statement "Information I receive about vaccines from the vaccine program is reliable and trustworthy". 3-level responses were collapsed from a 5-point Likert scale.



Figure 2. Map of Overall Mpox Acceptance by Province. (A) Reported acceptance as the collapsed responses of "Yes, for all populations" and "Yes, for children only" and "Yes, for

adults only" (B) Reported non-acceptance by the response "No, not interested". (C) Reported lack of knowledge of mpox disease. Percentages are reported by province.

(A)



(B)



(C)



Figure 3. Percent of Mpox Vaccine Acceptance by Province and Demographic Characteristic. Acceptance of an Mpox Vaccine among respondents as stratified by sociodemographic characteristics and known mpox risk factors COVID-19 vaccination was dichotomized by whether the respondent received the COVID-19 vaccine. Health condition was dichotomized based on whether the respondent stated they had a chronic disease or were immunocompromised.

* Chi-sq p-value <.05


Characteristic n Percent (95% CI)
*Province
Bas Uele 125 50.8 (44.6 to 57.0)
Equateur 77 47.8 (40.2 to 55.6)
Haut Katanga 141 66.8 (60.2 to 72.9)
Haut Lomami 20 40.8 (27.9 to 55.1)
Haut Uele 107 78.1 (70.4 to 84.3)
Ituri 134 56.3 (49.9 to 62.5)
Kasai 80 67.8 (58.8 to 75.6)
Kasai Central 32 37.6 (28.0 to 48.4)
Kasai Oriental 416 70.7 (66.9 to 74.3)
Kinshasa 182 72.8 (66.9 to 78.0)
Kongo Central 109 35.3 (30.1 to 40.8)
Kwango 154 84.2 (78.1 to 88.8)
Kwilu 375 58.3 (54.5 to 62.1)
Lomami 102 53.7 (46.5 to 60.7)
Lualaba 92 56.1 (48.4 to 63.5)
Maindombe 82 61.7 (53.1 to 69.5)
Maniema 84 85.7 (77.3 to 91.4)
Mongala 176 73.9 (68.0 to 79.1)
Nord Ubangi 95 84.1 (76.1 to 89.7)
North Kivu 85 60.7 (52.4 to 68.5)
Sankuru 35 19.9 (14.6 to 26.5)
Sud Kivu 82 55.8 (47.6 to 63.6)
Sud Ubangi 45 51.7 (41.2 to 62.1)
Tanganyika 129 85.4 (78.8 to 90.2)
Tshopo 74 51.4 (43.2 to 59.5)
Tshuapa 55 87.3 (76.5 to 93.6)
20 40 60 80 100


Characteristic n Percent (95% CI)
Gender
Female 609 58.5 (55.5 to 61.5)
Male 2479 61.7 (60.1 to 63.1)
*Education
Less than high school 215 60.9 (55.7 to 65.9)
Graduated high school 767 49.8 (47.3 to 52.3)
Some college 1391 66.7 (64.6 to 68.6)
Bachelor or advanced degree 715 66.1 (63.3 to 68.9)
*Occupation
Health worker 1947 69.4 (67.7 to 71.1)
Community leader 364 48.3 (44.7 to 51.8)
Public Servant or Educator 330 50.8 (46.9 to 54.6)
Religious leader 40 44.9 (34.9 to 55.4)
Other worker 287 58.8 (54.4 to 63.1)
Not working 120 43.6 (37.9 to 49.6)
*Geographic Area
Rural 1616 64.4 (62.5 to 66.2)
Urban 1472 57.7 (55.8 to 59.6)
*COVID-19 Vaccination
No 311 46.8 (43.0 to 50.6)
Yes 2777 63.2 (61.7 to 64.6)
*Health Condition
No 2815 62.2 (60.8 to 63.6)
Yes 273 51.0 (46.8 to 55.3)
30 40 50 60 70 80

225